2030-53-7 Usage
Uses
Used in Pharmaceutical Industry:
[7aS,(+)]-6,7,7a,8-Tetrahydro-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline is used as a potential pharmaceutical agent for its possible interactions with biological systems. Its unique structure may offer new avenues for drug development, targeting various diseases and conditions.
Used in Research and Development:
In the field of chemical research, [7aS,(+)]-6,7,7a,8-Tetrahydro-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline serves as a subject of study for understanding its chemical properties, reactivity, and potential applications. Researchers may investigate its synthesis, stability, and interactions with other compounds to uncover new insights and applications.
Used in Drug Discovery:
[7aS,(+)]-6,7,7a,8-Tetrahydro-7-methyl-5H-benzo[g]-1,3-benzodioxolo[6,5,4-de]quinoline is utilized in drug discovery processes to identify its potential as a therapeutic agent. Its unique structure may provide a foundation for the development of new drugs with novel mechanisms of action, addressing unmet medical needs.
Check Digit Verification of cas no
The CAS Registry Mumber 2030-53-7 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 2,0,3 and 0 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 2030-53:
(6*2)+(5*0)+(4*3)+(3*0)+(2*5)+(1*3)=37
37 % 10 = 7
So 2030-53-7 is a valid CAS Registry Number.
InChI:InChI=1/C18H17NO2/c1-19-7-6-12-9-15-18(21-10-20-15)17-13-5-3-2-4-11(13)8-14(19)16(12)17/h2-5,9,14H,6-8,10H2,1H3/t14-/m0/s1
2030-53-7Relevant academic research and scientific papers
Synthesis and evaluation of nuciferine and roemerine enantiomers as 5-HT2 and α1 receptor antagonists
Heng, Hui Li,Chee, Chin Fei,Chin, Sek Peng,Ouyang, Yifan,Wang, Hao,Buckle, Michael J.C.,Herr, Deron R.,Paterson, Ian C.,Doughty, Stephen W.,Abd Rahman, Noorsaadah,Chung, Lip Yong
, p. 576 - 582 (2018/03/28)
In this study, the (S)-enantiomers of the aporphine alkaloids, nuciferine and roemerine, were prepared via a synthetic route involving catalytic asymmetric hydrogenation and both stereoisomers were evaluated in vitro for functional activity at human 5-HT2 and adrenergic α1 receptor subtypes using a transforming growth factor-α shedding assay. Both enantiomers of each of the compounds were found to act as antagonists at 5-HT2 and α1 receptors. (R)-roemerine was the most potent compound at 5-HT2A and 5-HT2C receptors (pKb = 7.8-7.9) with good selectivity compared to (S)-roemerine at these two receptors and compared to its activity at 5-HT2B, α1A, α1B and α1D receptors.
